What is Spinal Kinetics?
Spinal Kinetics has developed and patented the Computerized Radiographic Mensuration Analysis (CRMA)® technology. This sophisticated system, utilized by Board Certified Medical Radiologists, accurately quantifies abnormal intersegmental motion in the spine, a critical indicator of spinal ligament injury and instability. Unlike MRI, which is not designed for this specific measurement, CRMA® provides unbiased, precise data essential for diagnosing the severity and location of spinal ligament damage. The company offers a streamlined service, enabling healthcare providers to integrate this advanced diagnostic capability into their practices with zero upfront cost, simply by submitting x-ray results for expert analysis within 24-48 hours.
How much funding has Spinal Kinetics raised?
Spinal Kinetics has raised a total of $40.4M across 3 funding rounds:
Unspecified
$5.3M
Private Equity
$33.8M
Debt
$1.3M
Unspecified (2009): $5.3M, investors not publicly disclosed
Private Equity (2014): $33.8M led by Lumira Capital, De Novo Ventures, SV Life Sciences, HLM Venture Partners, and BA Venture Partners
Debt (2016): $1.3M, investors not publicly disclosed
Key Investors in Spinal Kinetics
Lumira Capital
Lumira Capital is an investment firm that likely focuses on providing capital and strategic support to companies within the healthcare and life sciences sectors.
De Novo Ventures
De Novo Ventures is a venture capital firm that typically invests in early-stage companies, potentially within the medical technology or healthcare innovation space.
SV Life Sciences
SV Health Investors is a specialist investment firm backing innovative health care and life science companies, partnering with founders and management to provide capital, sector expertise and active support from early growth through scale and value creation.
What's next for Spinal Kinetics?
The substantial enterprise-level funding and recent strategic investment suggest Spinal Kinetics is poised for significant scaling and market expansion. This capital infusion is likely to accelerate the adoption of CRMA® technology, particularly given the high prevalence of spine-related injuries contributing to chronic pain and disability. The company's focus on providing a cost-effective, high-value diagnostic service positions it for growth within the healthcare provider network, aiming to enhance the diagnostic expertise available for spinal ligament damage and instability assessments.
See full Spinal Kinetics company page
